
Cryo-Cell International, Inc.: financial statements
Price
$4.85
November 13, 2026Market cap $39M
What Ploutos Investor adds for Cryo-Cell International
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from FY2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
+0.4% a year over 2 years
| Line | FY2023 | FY2024 | FY2025 | Average a year |
|---|---|---|---|---|
| Revenue | $31M | $32M | $32M | +0.4% |
| Cost of revenue | $8.4M | $7.9M | $7.4M | -6.2% |
| Gross profit | $23M | $24M | $24M | +2.7% |
| Operating income | -$12M | $3.5M | $482.4K | |
| Net income | -$9.5M | $402.1K | -$2.4M | |
| Earnings per share | -$1.14 | $0.05 | -$0.30 | |
| Earnings per share, basic | -$1.14 | $0.05 | -$0.30 | |
| Margins | ||||
| Gross margin | 73.2% | 75.2% | 76.6% | |
| Operating margin | -39.3% | 10.9% | 1.5% | |
| Net margin | -30.4% | 1.3% | -7.7% | |
Financial statements
CCEL's revenue, profits and cash flows from FY2010 to FY2022, 13 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
By segment
Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.
- Umbilical Cord Blood And Cord Tissue Stem Cell Service
- Public Cord Blood Banking
- Prepacytecb
- FY2023: Umbilical Cord Blood And Cord Tissue Stem Cell Service $31M, Public Cord Blood Banking $481.1K, Prepacytecb $66.5K
- FY2024: Umbilical Cord Blood And Cord Tissue Stem Cell Service $32M, Public Cord Blood Banking $366.7K, Prepacytecb $67.9K
- FY2025: Umbilical Cord Blood And Cord Tissue Stem Cell Service $31M, Public Cord Blood Banking $129.5K, Prepacytecb $54.1K
| Segment | FY2023 | FY2024 | FY2025 | Share FY2025 |
|---|---|---|---|---|
| Umbilical Cord Blood And Cord Tissue Stem Cell Service | $31M | $32M | $31M | 99% |
| Public Cord Blood Banking | $481.1K | $366.7K | $129.5K | 0.4% |
| Prepacytecb | $66.5K | $67.9K | $54.1K | 0.2% |
By segment
CCEL's revenue by segment from FY2017 to FY2022, 6 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
From the XBRL of 11 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
When the debt falls due
Nov 30, 2025Due within 2 years
$385.6K
Principal of loans and bonds falling due, from the annual report dated November 30, 2025, without leases and interest. The filing
- 11/2026: $183.7K
- 11/2027: $202.0K
Leases
Nov 30, 2025Operating leases
$904.8K
Finance leases
–
The liability is the present value of the rent still to pay, at November 30, 2025. It is not counted in the ladder's debt. The filing
Goodwill by segment
Nov 30, 2025Total goodwill
$1.9M
The company does not state its goodwill by segment, at November 30, 2025. The filing
From the statutory to the effective tax rate, FY2025
Nov 30, 2025Statutory rate
21.0%
Effective rate
-4.0%
The company paid -4.0% in tax on its profit, 24.9 points below the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
Deferred Adjustment
-13.9 pts
Difference the filing does not itemize
-11.1 pts
Effective rate
-4.0%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Claims ahead of shareholders
What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.
Other than debt, no claim large enough to list ranks ahead of the shares.
From the balance sheet of August 31, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 13, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.
Earnings quality
How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.
Receivables and inventory against sales
In the quarter to Aug 31, 2026, sales were -0.0% on the same quarter a year earlier, and receivables +0.0%. Inventory was -18.6%, against -10.5% for the cost of sales.
- a year earlier 80 days
- 80 days
- a year earlier 33 days
- 30 days
Balances at Aug 31, 2026 and Aug 31, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.
Allowance for doubtful accounts
The allowance for receivables that may not be collected was 39.0% of gross receivables at Aug 31, 2026, against 39.3% a year earlier.
At last year's share it would be $30.1K larger. A smaller allowance means a smaller charge for bad debts in profit.
- a year earlier $4.4M
- $4.4M
Taxes: deferred and paid
The deferred part was -3,056.4% of the tax charge in the year to Nov 30, 2025. The rows show the last 2 years.
Cash taxes paid were 157.8% of the current tax charge in the year to Nov 30, 2025.
- Deferred share, year to Nov 30, 2025-$2.8M of $92.2K
- -3,056.4%
- Deferred share, year to Nov 30, 2024-$309.0K of $2.4M
- -12.9%
- $4.6M paid, $2.9M current
- 157.8%
When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.
The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.
A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.
The full analysis
What do Cryo-Cell International's filings show?
These are Cryo-Cell International's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did CCEL have in FY2025?
Cryo-Cell International had revenue of $32M and net income of -$2.4M in fiscal FY2025, a net margin of -7.7%.
How much debt does CCEL have?
On November 30, 2025 Cryo-Cell International had total assets of $62M, debt of $8.5M and shareholders' equity of -$19M.
How much free cash flow does CCEL have?
In fiscal FY2025 Cryo-Cell International had cash from operations of $5.5M and spent $230.5K on capital expenditure, leaving $5.2M of free cash flow.
Where are the figures from?
From Cryo-Cell International, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.